Nanocarriers as an emerging platform for cancer therapy

Dan Peer; Jeffrey M. Karp; Seungpyo Hong; Omid C. Farokhzad; Rimona Margalit; Robert Langer

doi:10.1038/nnano.2007.387

Nanocarriers as an emerging platform for cancer therapy

Dan Peer^*, Jeffrey M. Karp, Seungpyo Hong, Omid C. Farokhzad, Rimona Margalit, Robert Langer

^*Corresponding author for this work

Biochemistry Molecular Biology

Research output: Contribution to journal › Review article › peer-review

7768 Scopus citations

Abstract

Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.

Original language	English
Pages (from-to)	751-760
Number of pages	10
Journal	Nature Nanotechnology
Volume	2
Issue number	12
DOIs	https://doi.org/10.1038/nnano.2007.387
State	Published - Dec 2007

Funding

Funders	Funder number
NIH/NCI	CA119349
NIH/NIBIB	EB 003647
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering	R01EB000244

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nnano.2007.387

Cite this

@article{8132967dfeef41429600835c400579bb,

title = "Nanocarriers as an emerging platform for cancer therapy",

abstract = "Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.",

author = "Dan Peer and Karp, {Jeffrey M.} and Seungpyo Hong and Farokhzad, {Omid C.} and Rimona Margalit and Robert Langer",

note = "Funding Information: We would like to acknowledge Shiladitya Sengupta for critically reviewing the manuscript and Maeve Cullinane for helpful discussions. This work was supported by federal funds NIH/NCI CA119349, NIH/NIBIB EB 003647, and NIH R01-EB000244. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.",

year = "2007",

month = dec,

doi = "10.1038/nnano.2007.387",

language = "אנגלית",

volume = "2",

pages = "751--760",

journal = "Nature Nanotechnology",

issn = "1748-3387",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Nanocarriers as an emerging platform for cancer therapy

AU - Peer, Dan

AU - Karp, Jeffrey M.

AU - Hong, Seungpyo

AU - Farokhzad, Omid C.

AU - Margalit, Rimona

AU - Langer, Robert

N1 - Funding Information: We would like to acknowledge Shiladitya Sengupta for critically reviewing the manuscript and Maeve Cullinane for helpful discussions. This work was supported by federal funds NIH/NCI CA119349, NIH/NIBIB EB 003647, and NIH R01-EB000244. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

PY - 2007/12

Y1 - 2007/12

N2 - Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.

AB - Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=36849067019&partnerID=8YFLogxK

U2 - 10.1038/nnano.2007.387

DO - 10.1038/nnano.2007.387

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:36849067019

SN - 1748-3387

VL - 2

SP - 751

EP - 760

JO - Nature Nanotechnology

JF - Nature Nanotechnology

IS - 12

ER -

Nanocarriers as an emerging platform for cancer therapy

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this